# Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

Maud Maillard, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas Cabaton, Frédéric Pont, Nathalie Saint-Laurent, Thierry Lafont, Etienne Chatelut, Fabienne Thomas

► To cite this version:

Maud Maillard, Cécile Arellano, Christelle Vachoux, Christine Chevreau, Nicolas Cabaton, et al. Bi- ological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury. Metabo- lites, 2022, 12 (9), pp.852. 10.3390/metabo12090852. hal-03799313

HAL Id: hal-03799313

https://hal.inrae.fr/hal-03799313

Submitted on 5 Oct 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Article

# Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury

Maud Maillard<sup>1,2</sup>, Cécile Arellano<sup>1</sup>, Christelle Vachoux<sup>1</sup>, Christine Chevreau<sup>2</sup>, Nicolas J. Cabaton<sup>3,□</sup>, Frédéric Pont<sup>1,□</sup>, Nathalie Saint-Laurent<sup>1</sup>, Thierry Lafont<sup>1,2</sup>, Etienne Chatelut<sup>1,2</sup> and Fabienne Thomas<sup>1,2,*□</sup>

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Maillard, M.; Arellano, C.; Vachoux, C.; Chevreau, C.; Cabaton, N.J.; Pont, F.; Saint-Laurent, N.; Lafont, T.; Chatelut, E.; Thomas, F. Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury.
*Metabolites* **2022**, *12*, 852. https://doi.org/10.3390/metabo12090852

Academic Editor: Ala F. Nassar

Received: 13 August 2022

Accepted: 9 September 2022

Published: 11 September 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Tyrosine kinase inhibitors pazopanib and sunitinib are both used to treat advanced renal cell carcinoma but expose patients to an increased risk of hepatotoxicity. We have previously identified two aldehyde derivatives for pazopanib and sunitinib (P-CHO and S-CHO, respectively) in liver microsomes. In this study, we aimed to decipher their role in hepatotoxicity by treating HepG2 and HepaRG hepatic cell lines with these derivatives and evaluating cell viability, mitochondrial dysfunction, and oxidative stress accumulation. Additionally, plasma concentrations of P-CHO were assessed in a cohort of patients treated with pazopanib. Results showed that S-CHO slightly decreased the viability of HepG2, but to a lesser extent than sunitinib, and affected the maximal respiratory capacity of the mitochondrial chain. P-CHO decreased viability and ATP production in HepG2. Traces of P-CHO were detected in the plasma of patients treated with pazopanib. Overall, these results showed that P-CHO and S-CHO affect hepatocyte integrity and could be involved in the pazopanib and sunitinib hepatotoxicity.

**Keywords:** aldehyde; hepatotoxicity; pazopanib; reactive metabolites; sunitinib

## 1. Introduction

Drug-induced liver injuries (DILIs) are the primary cause of acute liver failure and drug withdrawal in the United States, where they represent a major clinical and economic concern for healthcare [1]. Pazopanib (Votrient®) and sunitinib (Sutent®) are two oral tyrosine kinase inhibitors (TKIs) used to treat metastatic renal cell carcinoma (mRCC). Both drugs are “black-boxed” by the U.S. Federal Drug Administration (FDA) for an increased risk of acute hepatotoxicity [2,3]. The mechanisms of TKI-induced liver toxicity are not fully understood, but recent works have highlighted its multifactorial etiology; particular interest has been shown in the formation of reactive metabolites from the biotransformation of TKIs such as lapatinib [4], famitinib [5], pazopanib, sunitinib [6], and more recently, olmutinib [7]. Their toxic potential is thought to be caused by their propensity to generate electrophilic radicals or moieties (such as aldehydes or intermediate semi-quinone radicals leading to reactive quinone imines) that can covalently bind intracellular components, affect cell structure, and induce cell death. These structural alert patterns may result from the biotransformation of the parent molecule by phase I enzymes such as cytochromes P450 (CYP450), making the liver the privileged place for their production [8].

Alteration of the structure and/or function of mitochondria is supposed to cause DILIs [9]. This hypothesis has been reported for ponatinib, regorafenib, sorafenib [10], sunitinib [11,12], and lapatinib [4] in the hepatocarcinoma cell line HepG2 and for crizotinib, dasatinib, ponatinib, regorafenib, and sorafenib in human HepaRG cells [13]. However,

<footnote n="1">¹ Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, Université Toulouse III-Paul Sabatier, 2 Avenue Hubert Curien, CS53717, CEDEX 1, 31037 Toulouse, France</footnote>

<footnote n="2">² Institut Claudius Regaud IUCT-Oncopole, CEDEX 9, 31059 Toulouse, France</footnote>

<footnote n="3">³ Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRAE, ENVT, INP-Purpan, UPS, 31027 Toulouse, France</footnote>

<footnote>* Correspondence: thomas.fabienne@iuct-oncopole.fr; Tel.: +33-(0)531155574</footnote>
except for lapatinib, the involvement of reactive metabolites has not yet been investigated, and studies have only focused on parent molecule-induced toxicity.

Using metalloporphyrin, a chemical catalytic system that mimics specific CYP450-type oxidation, our team has previously identified two aldehyde derivatives for pazopanib and sunitinib [14]. Their reactivity was shown by the in vitro detection of covalent adducts to lysine in liver microsomes and recombinant CYP3A4 incubations.

In this study, we question the putative role of pazopanib and sunitinib aldehyde derivatives in their clinical hepatotoxicity. To this end, we evaluated the ability of these aldehydes to impair hepatocyte viability by focusing on the mitochondrial function and the accumulation of intracellular oxidative stress. Finally, we attempted to evaluate the relationship between plasma concentrations of pazopanib aldehyde and clinical hepatic side effects reported for patients treated with pazopanib for mRCC.

**2. Materials and Methods**

**2.1. Chemicals and Solvents**

Sunitinib L-malate and pazopanib hydrochloride (HCl) were purchased from Al-sachim (Illkirch Graffenstaden, France, purity > 98%). Aldehyde metabolites of pazopanib (P-CHO) and sunitinib (S-CHO) were synthesized by chemical synthesis (Institut de Chimie et Biochimie Moléculaires et Supramoléculaires ICBMS, Université Claude Bernard, Villeurbanne, France). Structures were confirmed by NMR and LC-MS analysis. Stock solutions were prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA) and stored at -20 °C. Pazopanib HCl was dissolved in dimethylformamide (DMF) for UPLC-MS/MS analysis. L-buthionine sulfoximine (BSO), sodium cyanoborohydride (NaBH₃CN), and ammonium formate were purchased from Sigma-Aldrich; formic acid was provided by Merck (Darmstadt, Germany). Acetonitrile and methanol were provided by Biosolve (Valkenswaard, The Netherlands, UPLC-MS/MS grade) and isopropanol was purchased from Merck. Blank plasma from healthy donors was provided by the French National Blood Service (EFS, Toulouse, France).

**2.2. Cell Culture**

Two hepatic cell lines were used to evaluate the cytotoxicity of P-CHO and S-CHO. The human hepatocarcinoma cell line HepG2 (ATCC reference HB-8065) was maintained in complete high-glucose media (Dulbecco's modified Eagle Medium, DMEM, glucose 4.5 g/L, Sigma) supplemented with 10% (v/v) of fetal bovine serum (FBS), 0.1% of antimycotic solution (Plasmocin™ prophylactic, InvivoGen, Toulouse, France), and 1% of an antibiotic cocktail (penicillin and streptomycin, Thermo Fisher Scientific, Waltham, MA USA). For culture in glucose-depleted conditions, the medium was replaced with complete medium supplemented with 10 mM galactose, 2 mM L-glutamine, antibiotic-antimycotic solution, 5 mM HEPES, and 1 mM sodium pyruvate.

The cytotoxicity experiments with the HepaRG cell line were performed at the INRAE/Toxalim Institute (Toulouse, France). Before experimental usage, they were seeded for two weeks at a density of 2.6 × 10⁴ cells/cm² in a growth medium composed of Williams' E medium supplemented with 10% FCS, 100 units/mL penicillin, 100 mg/mL streptomycin, 5 mg/mL insulin, 2 mM glutamine, and 5 × 10⁻⁵ M hydrocortisone hemisuccinate. After two weeks, cells were shifted to the same culture medium supplemented with 2% DMSO (differentiation medium) for two additional weeks (confluent DMSO-treated cells) [15]. The medium was renewed every two to three days.

**2.3. LDH Release, Caspase 3/7 Activation and ATP Measurement**

Acute cytotoxicity was assessed by measuring the LDH liberation following membrane damage with the CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Promega, Madison, WI, USA). Briefly, HepG2 cells were seeded at 20,000 cells per well and exposed for 24 h to increase the concentrations of components (1–100 µM for sunitinib, S-CHO, and P-CHO and 1–50 µM for pazopanib due to its limited solubility in aqueous media).
HepaRG cells were seeded at 50,000 cells per well and were exposed to the molecules 24 h later for 24 h. The negative control was the DMSO maximal level, with Triton® X-100 as the positive control. Depletion of intracellular glutathione was induced by pre-treating cells with 250 µM of BSO 24 h prior to drug administration. Fluorescence (560/590 nm) was recorded using a Clariostar plate reader (BMG Labtech, Ortenberg, Germany) for HepG2 cells and a Tecan Infinite 200 (Lyon, France) for HepaRG cells. Data were integrated with Mars Data Analysis software (v.1.51, BMG Labtech) and iControl V1.30 software. Induced apoptosis was investigated by measuring caspase 3/7 activity with the Caspase-Glo® 3/7 luminescent assay (Promega). Proportional luminescence was recorded using a plate reader. ATP content was assessed in cells cultured in high-glucose or galactose media with the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) after cell lysis.

## 2.4. Evaluation of the Mitochondrial Respiration in HepG2 Cells

Cellular respiration was measured with the mitochondrial oxygen consumption rate (OCR, expressed in pmol O₂/min) in HepG2 with Seahorse XF Cell Mito Stress for a Seahorse XF24e analyzer (Seahorse Biosciences, North Billerica, MA, USA). Cells were seeded at a concentration of 20,000 cells/well in high-glucose medium and were exposed to aldehydes at non-toxic concentrations (1–40 µM). One hour before the experiment, the medium was replaced by a low-glucose solution (Agilent, Santa-Clara, CA, USA) supplemented with pyruvate 1 mM, glutamine 2 mM, and glucose 10 mM. NaOH 0.1 M was used to adjust the pH to 7.4. The plate was incubated at 37 °C, 0% CO₂ for one hour. Mitochondrial respiratory chain inhibitors were prepared in that freshly made medium. The assay consisted in measuring basal respiration followed by the sequential addition of an ATP synthase inhibitor, oligomycin (2 µM), followed then by maximal stimulation of the mitochondrial electron transport chain by adding carbonyl cyanide m-chlorophenylhydrazone (CCCP, 2 µM, an uncoupling agent dissipating the proton gradient). Finally, adding rotenone- and antimycin A- (0.5 µM each) inhibited mitochondrial complexes I and III, respectively, and allowed us to determine extramitochondrial respiration. Maximal respiratory capacity was calculated after subtracting extramitochondrial respiration. The assay was conducted over 96 min, and data were normalized to the protein content with the Pierce™ BCA Protein Assay Kit (ThermoFisher, Waltham, MA, USA).

## 2.5. Mitochondrial Superoxide Accumulation in HepG2 Cells

The accumulation of mitochondrial superoxide was assessed in live cells using the selective MitoSOX™ Red Mitochondrial Superoxide Indicator (Invitrogen, Waltham, MA, USA). To evaluate the role of GSH in aldehyde detoxication, cells were exposed to an increasing range of reactive metabolites (1–50 µM) in either the presence or absence of BSO (250 µM), a specific inhibitor of GSH synthesis. Rotenone (50 µM) was used as a positive control. After treatment, cells were gently washed with PBS and covered with 2.5 µM of MitoSOX reagent diluted in PBS. Fluorescence was recorded after incubation (excitation/emission wavelength 510 nm/580 nm), and data were normalized to the protein concentration.

## 2.6. Superoxide Dismutases 1 and 2 Gene Expression in HepG2 Cells

Expression of superoxide dismutase1 and 2 encoding genes (*SOD1* and *SOD2*, respectively) was measured by quantitative polymerase in chain reactions (qPCR) in HepG2 cells exposed to 20 µM of components for either two or six hours. RNA was extracted with the Qiagen RNEasy mini kit (Qiagen, Hilden, Germany) and reverse transcription was performed with the Biorad iScript™ Reverse Transcription Supermix (Biorad, Hercules, CA, USA). The qPCR reaction mix was prepared with SYBR® Green Master Mix (Biorad), 20 µM of corresponding forward and reverse primers designed with BLAST® (https://blast.ncbi.nlm.nih.gov/Blast.cgi, accessed on 24 March 2022) (*SOD1*, 5'-GCAGGTCCTCACTTTAATCC-3' and 5'-GCCACACCATCTTTGTCA-3'; *SOD2*, 5'-GGGTTGGCTTGGTTTCAA-3' and reverse 5'-GTGCTCCCACACATCAATC-3'; reference gene β2-microglobulin [B2M], 5'-
TGAGTGCTGTCTCCATGTTTG-3′ and 5′-TCTGCTCCCCACCTCTAAGTT-3′) and free-DNase water. Amplification was performed in triplicates and repeated on two or three distinct RNA extractions. Expression levels were calculated with the 2⁻⁰⁻ΔΔCt method using a DMSO 0.1% sample as the calibrator and considering a PCR efficiency of 100% [16].

## 2.7. Proteomic Analysis

A proteomic analysis was conducted to identify the interaction sites of aldehyde metabolites with human liver microsomal proteins. P-CHO and S-CHO (20 µM) were incubated with liver microsomes (0.25 mg/mL, ref. #452161, Corning, NY, USA; Bedford, UK) for 90 min. Irreversible binding was allowed by reductive amination with NaBH₃CN. Protein purification was performed by one-dimension polyacrylamide gel electrophoresis (1D-PAGE) with the use of sodium dodecyl sulfate (SDS). The bands were reduced and alkylated by D, L-dithiothreitol DTT (10 mM), and 2-chloroacetamide (55 mM) and were digested with trypsin. Peptides were diluted in a buffer containing 10% ACN and 0.05% trifluoroacetic acid. Samples were analyzed by HPLC coupled to a SCIEX 5600 + TripleTOF mass spectrometer. Peptide identification was performed with an MSFragger database search tool applied to the SwissProt human database coupled to research in the Protein DataBank (PDB; http://www.rcsb.org/pdb/, accessed on 24 March 2022). Additional information about mass spectrometry and data analyses can be found in the Supplementary Material.

## 2.8. Patients and Hepatotoxicity Data

Correlations between plasma concentrations of P-CHO and liver parameters were evaluated in 15 patients treated with pazopanib for mRCC and included in the SUP-R clinical trial ((ClinicalTrials.gov Identifier: NCT02555748)), a French pilot study evaluating sunitinib and pazopanib pharmacokinetic parameters and toxicity. Patients were sampled on the first day of the first treatment cycle before intake (T0), and at two, four, six, and eight hours after intake (T2, T4, T6, T8). This schedule was repeated at T0, T2, and T6 on the 15th day of cycle 1 and cycle 2. Patients' hepatic biochemical parameters were collected before inclusion and during treatment and were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, v.4.03).

## 2.9. Preparation of Patients' Samples for Pazopanib Aldehyde Quantification

The procedure to extract P-CHO from plasma was slightly adapted from our previous work [6]. Briefly, 250 µL of plasma were precipitated with 750 µL of acetonitrile and centrifuged at 1500 × g for 20 min at 4 °C. The supernatant was dried at 37 °C until complete solvent evaporation. The extract was dissolved in a mixture composed of methanol and aqueous mobile phase (75/25%), filtered, and analyzed. For quantification, plasma P-CHO standard solutions (0.49 to 250 ng/mL) were prepared and extracted extemporaneously. The experimentation was validated if at least two out of three quality control (QC) samples were ±15% of the targeted value for medium (40 ng/mL) and high (200 ng/mL) QC and ±20% for low QC (2.5 ng/mL).

## 2.10. UPLC-MS/MS Analysis

Extracted samples were analyzed with a UPLC Waters Acquity system equipped with a Waters TQ-S micro mass spectrometer (triple quadrupole detector) added to an electrospray ionization source (ESI). Components were eluted in a linear gradient with sequential changes in the proportion of aqueous eluent (ammonium formate in ultrapure water, pH = 3.2) and organic eluent (acetonitrile with formic acid 0.1% [v/v]), as previously described [6]. Data were analyzed with MassLynx software (version 4.2, Waters, Milford, MA, USA). The multiple reaction monitoring (MRM) mode was used for mass spectrometry detection. Selected MRM characteristic transitions were 438.0 > 357.0 (loss of SO₂NH₂) for pazopanib, 452.0 > 328.0 (loss of SO₂NH₂, CHO and CH₃) and 452.0 > 343.0 (loss of SO₂NH₂ and CHO) for P-CHO. S-CHO was detected with 413.1 > 340.1 (loss of N(CH₂CH₃)₂),
413.1 > 297.1 (loss of N(CH₂CH₃)₂-(CH₂)₂-NH-CO), and 413.1 > 268.1 (cleavage of the amide bond and loss of CHO).

## 2.11. Statistical Analyses

All experiments were conducted three times, so the data are given as the mean ± standard deviation (s.d.). A one-way ANOVA followed by Dunnett's post-test procedure was used for comparison with vehicle control. A two-way ANOVA followed by Bonferroni's post-test procedure was used to compare multiple conditions. *p* value < 0.05 was considered significant. Statistical analyses were performed with R® version 4.1.0 (R Foundation for Statistical Computing, Vienna, Austria) and plots were created with GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA).

# 3. Results

## 3.1. Evaluation of Pazopanib and Sunitinib Aldehyde Cytotoxicity in Liver Cell Lines

The chemical structures of pazopanib, sunitinib, and their derived aldehydes (P-CHO and S-CHO, respectively) are presented in Figure 1.

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Chemical structures of pazopanib, sunitinib, and aldehyde derivatives (P-CHO and S-CHO, respectively).</figcaption></figure>

Acute cytotoxicity was tested by exposing HepG2 and HepaRG cells to parent molecules or metabolites for 24 h (1–100 µM, 1–50 µM for pazopanib, due to its limited solubility in aqueous media) and then measuring the release of lactate dehydrogenase (Figure 2). Pazopanib did not affect cell viability at any concentration in both cell lines (Figure 2A,C). In contrast, P-CHO started to be slightly cytotoxic at a concentration of 50 µM with a significant difference at this level compared to pazopanib. Sunitinib and S-CHO both induced cell lysis at 50 µM, with sunitinib having a greater toxic effect (*p* < 0.01) (Figure 2B) in HepG2 cells. As the cytotoxicity of S-CHO was confirmed with the HepaRG cell line (Figure 2D), the rest of the experiments were performed with the HepG2 cell line.

The activation of apoptosis was evaluated by measuring the activity of caspases 3 and 7. Apoptosis was increased two-fold when cells were exposed to high concentrations of P-CHO (Figure 3A), and both sunitinib and S-CHO activated apoptosis in a concentration-dependent way (Figure 3B).

## 3.2. Evaluation of the Effect of Pazopanib and Sunitinib Aldehydes on Mitochondrial Function in the HepG2 Cell Line

HepG2 cells were conditioned in galactose complete media to switch cellular ATP production from glycolysis to mitochondrial oxidative phosphorylation. As shown in Figure 4A, P-CHO induced a concentration-dependent decrease in ATP starting at 20 µM, especially in HepG2 cells cultured in galactose. No difference, however, was observed
in the glucose culture. S-CHO 100 µM depleted 80% of the ATP content of HepG2 cells cultured in galactose (Figure 4B), whereas it induced lysis in only 50% of cells (Figure 2B).

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

<figure><img src="image_9.png" /></figure>

**Figure 2.** Cytotoxicity on hepatocytes exposed to pazopanib, sunitinib, and their respective aldehydes. Drug cytotoxicity was assessed by measuring lactate dehydrogenase release after 24-h exposure to increasing concentrations of compounds in HepG2 cells (A,B) and HepaRG cells (C,D). Results are given as mean and standard deviation (s.d.). \* *p* < 0.05 in comparing the parent molecule versus the aldehyde metabolite.

<figure><img src="image_10.png" /></figure>

<figure><img src="image_11.png" /></figure>

**Figure 3.** Activation of apoptosis in HepG2 cells exposed to pazopanib, sunitinib, and their respective aldehydes. Apoptosis was evaluated in HepG2 cells by measuring caspases 3 and 7 activity in the presence of pazopanib or P-CHO (A) and sunitinib or S-CHO (B). Results are given as mean and standard deviation (s.d.) of fold-change of caspases activation compared to control. \* *p* < 0.05 in comparing the parent molecule versus the aldehyde metabolite.

Mitochondrial respiration was assessed by using a Seahorse XF24e analyzer to measure the oxygen consumption rate (OCR) of HepG2 cells exposed to aldehydes. P-CHO and S-CHO effects on respiratory capacity were tested at concentrations that did not affect cell viability (1–40 µM). As depicted in Figure 4C,E, P-CHO initially increased the mitochondrial respiratory function, and a slight but significant decrease was observed from 10 µM to 40 µM, especially for ATP production. S-CHO did not affect ATP production (Figure 4D),
but a significant decrease in maximal respiratory capacity was observed at the highest concentrations tested (30 and 40 µM) (Figure 4F).

<figure><img src="image_12.png" /><figcaption>**Figure 4.** Pazopanib and sunitinib aldehydes impair mitochondrial function. Mitochondrial function was assessed in HepG2 cells by detecting intracellular ATP in cells cultured in a glucose (solid line) or a galactose (dotted line) medium and exposed to increasing concentrations of P-CHO (A) or S-CHO (B). Relative oxygen consumption rate (OCR) was measured by Seahorse assay in HepG2 cells cultured in a glucose medium. ATP production and Maximal Respiratory Capacity were evaluated for P-CHO (C,E) and S-CHO (D,F) and were expressed as the fold-change of OCR measured in non-treated cells. \* *p* value < 0.05 compared to non-treated cells.</figcaption></figure>

### 3.3. Evaluation of Oxidative Stress in the Presence of Reactive Metabolites

To investigate the propensity of P-CHO and S-CHO to induce oxidative stress, cells were cultured both with and without BSO, which is known to reduce glutathione cellular levels by inhibiting γ-glutamylcysteine synthetase. In Figure 5, mitochondrial superoxide was detected by means of the MitoSOX indicator in live HepG2 cells and compared with superoxide dismutase (SOD) expression in response to oxidative stress.

The increase in mitochondrial superoxide was marked in HepG2 cells exposed to a high concentration of pazopanib in the presence of BSO (i.e., 50 µM in the absence of glutathione, Figure 5A). In contrast, it only slightly accumulated in a concentration-dependent manner in cells exposed to P-CHO, with no difference between the presence or absence of BSO except at high concentrations (Figure 5B). S-CHO treatment did not result in an accumulation of reactive mitochondrial species under normal conditions, contrary
to sunitinib, especially at its highest concentration (Figure 5C,D). Glutathione depletion favored superoxide accumulation in the presence of aldehydes without increasing their cytotoxicity (see Supplementary Figure S1).

<figure><img src="image_13.png" /><figcaption>**Figure 5.** Production of mitochondrial superoxide and superoxide dismutase expression (SOD) in response to the accumulation of oxidative stress in HepG2 cells. Mitochondrial superoxide was measured after exposure to increasing concentrations of pazopanib (A), sunitinib (B), P-CHO (C), or S-CHO (D) with or without BSO that depleted intracellular glutathione. Response to the oxidative stress accumulation after 20 µM of P-CHO and S-CHO was evaluated by means of the relative gene expression of *SOD1* (E,F, respectively) and *SOD2* (G,H, respectively) measured in HepG2 cells cultured in either glucose or galactose media and incubated for either two or six hours. Expression levels are expressed as a fold-change compared with controls and results from two or three independent experiments (mean ± s.d.). \* *p* value < 0.05 for BSO vs. non-BSO comparison. \# *p* value < 0.05 for comparison with non-treated cells.</figcaption></figure>

To evaluate the response to possible superoxide production, *SOD1* and *SOD2* expression was measured by quantitative RT-PCR in HepG2 cells exposed to 20 µM of P-CHO or S-CHO in galactose (i.e., mitochondrial production of ATP) and high-glucose (i.e., ATP
production from glycolysis) media for either two or six hours. Results showed that neither expression of *SOD1* nor *SOD2* was affected in the presence of P-CHO (Figure 5E,F) or S-CHO (Figure 5G,H), except for a slight increase in fold-change mRNA for *SOD1* in cells exposed to P-CHO for six hours in a galactose medium (Figure 5E, non-significant result).

### 3.4. Proteomic Analysis of Aldehyde Binding to Liver Microsomes Proteins

P-CHO and S-CHO adducts to lysin residues were previously identified in a microsomal fraction of the human liver [6]. Given that protein adducts can contribute to reactive metabolites toxic effects, we attempted to identify the microsomal proteins targeted by our aldehydes by high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS/MS). The total ion chromatogram of the digested microsomes incubated with P-CHO is shown in Supplementary Figure S2. A peptide belonging to the CYP450 coenzyme NADPH-cytochrome P450 reductase was shown to be modified by P-CHO in the histidine located at position 583 (Figure 6 and Supplementary Table S1). The fragmentation MS/MS spectrum can be found in Supplementary Figure S3.

<figure><img src="image_14.png" /><figcaption>**Figure 6.** Pazopanib aldehyde interaction with NADPH-cytochrome P450 oxidoreductase. The structure of the POR enzyme (PDB reference: 3QFS [17]) is depicted here with the major cofactors NADP and FAD. The enlarged view focuses on His583 modified by P-CHO after incubation with microsomes.</figcaption></figure>

### 3.5. Detection and Origin of Aldehyde Metabolites In Vivo

To determine if the clinical hepatotoxicity of pazopanib could be related to the production of its aldehyde derivative, we measured the plasma concentrations of P-CHO in 15 patients included in the SUP-R clinical trial.

Traces of P-CHO were detected (mean concentration = 6.45 ng/mL, s.d. = 4.30 ng/mL) in the plasma with concentrations showing similar kinetic profiles compared to pazopanib. The median metabolite: parent molecule ratio was 0.026% ([min = 0.009%; max = 1.924%], and Spearman's rank correlation was $\rho = 0.75, p < 0.001$).

In the cohort, five patients had at least one abnormality of liver biochemistry (all grades and all cycles included). P-CHO mean residual concentration at day 15 of the first cycle was 9.16 ng/mL (±3.65 ng/mL), not significantly different from that of patients with no liver abnormality (mean concentration = 7.21 ng/mL (±3.35 ng/mL), Wilcoxon's signed-rank *p* = 0.639). S-CHO could not be quantified in patients' plasma because of analytical issues. Notably, we attempted to decipher the origin of P-CHO and S-CHO by incubating pazopanib with microsomes in the presence of specific inhibitors of CYP450 and with cytosol with inhibitors of alcohol dehydrogenase, as aldehydes may result from alcohol oxidation. All methods and results are detailed in the Supplementary section. Only small amounts of aldehyde were detected, and the signal was at its highest level in inactive microsomes, meaning that the contribution of hepatic enzymes in their formation is probably minor (Supplementary Figure S4).
Moreover, we observed residual signals of P-CHO and S-CHO in microsomal and cytosolic incubations, thus we sought to detect these aldehydes in plasma spiked with pharmaceutical tablets of pazopanib (Votrient®) and capsules of sunitinib (Sutent®) (Supplementary Material). The amount of P-CHO was 7-fold lower in commercial tablets than in the plasma of patients treated with pazopanib (37 ppm vs. median of 260 ppm, respectively). Conversely, the S-CHO level reached 210 ppm of the total amount of sunitinib extracted from commercial capsules, a value equivalent to the proportions measured in the microsomal (260 ppm) and cytosolic incubations (330 ppm).

## 4. Discussion

Identifying the causes and risk factors of pazopanib and sunitinib induced-hepatotoxicity is part of the challenge of improving these inhibitors' management in metastatic renal cancer patients. However, understanding the mechanistic features resulting from liver damage is limited due to their complex and multifactorial origin [18]. After identifying pazopanib- and sunitinib-reactive aldehyde metabolites (P-CHO and S-CHO, respectively) [14], we evaluated their ability to induce hepatocyte cytotoxicity, mitochondrial dysfunction, and the accumulation of oxidative stress.

We observed that P-CHO exerted a cytotoxic effect at high concentrations (>50 µM) on the immortalized HepG2 cell line by activating apoptosis and impairing ATP synthesis, and we confirmed that pazopanib was not toxic in this case [13]. On the contrary, significant concentration-dependent toxicity and apoptosis activation were observed for sunitinib and its aldehyde. When using the HepaRG cell line that preserves more physiological characteristics, the function of human hepatocytes (especially phase I and phase II xenobiotic metabolism enzyme activities), and the expression of liver-specific genes [19], P-CHO toxicity was limited. S-CHO, however, affected cell viability to a greater extent than in HepG2 cells. These observations underlined the functional differences between the two cell lines in their ability to metabolize and eliminate drugs, as previously demonstrated by Paech et al. for sunitinib [20].

Important changes in mitochondria function and oxidative metabolism have been observed in cells treated with sunitinib. At high concentrations (>20 µM), sunitinib can inhibit both hepatic mitochondrial proliferation and respiration and reduce the glycolytic flux in HepG2 cells [12,20]. We completed these observations by showing that its aldehyde metabolite, S-CHO, decreases the maximal respiration rate in a concentration-dependent manner as it was demonstrated for its parent molecule, but it does not impact ATP production. Pazopanib-induced mitochondrial damages were less pronounced in a previous study [13], as it inhibited glycolysis only at high concentration (20 µM). Here, we showed that P-CHO impairs the ATP production in HepG2, especially when the cell relies on oxidative phosphorylation. Mitochondrial function or structure impairment can result in the increase of reactive oxygen species (ROS), such as mitochondrial superoxide, particularly when mitochondrial complexes III and I are inhibited [21]. Glutathione (GSH) is of paramount importance in protecting cells from accumulating ROS, and depletion is often associated with increased toxicity [22]. In our study, depleting GSH did not increase the accumulation of mitochondrial superoxide in cells exposed to aldehydes. Additionally, aldehydes did not significantly affect the expression of superoxide dismutases 1 and 2, two key regulators of ROS accumulation described as cytoplasmic and mitochondrial stress biomarkers [23]. Overall, both metabolites affect mitochondria in a different way that may reflect the effect of parent molecules on cell function.

In our previous study, we demonstrated that P-CHO and S-CHO can covalently bind the lysine residues of human proteins such as aldehyde-spiked albumin and plasma [6] when generated through biomimetic oxidations catalyzed by metalloporphyrin, HLM, and rCYP3A4. In this study, using a proteomic approach, we identified NADPH-cytochrome P450 reductase (POR) as a target of P-CHO. Crystal structure studies are needed to specifically identify local interactions between POR critical domains and P-CHO. This enzyme is essential in transferring electrons from NADPH, but large adducts located in the flavin
cofactor domains may interfere with this critical step of the CYP450 reaction cycle [24]. POR has been demonstrated to generate ROS spontaneously, such as hydrogen peroxide ($H_2O_2$) and mitochondrial superoxide, as a result of molecular oxygen reduction by its flavin cofactors [25]. We observed a weak accumulation of superoxide at high concentrations (>100 µM) of P-CHO, meaning that the limited accumulation of ROS in HepG2 cells could result from POR inhibition by P-CHO adduct formation. Gray et al. [26] previously observed a similar effect of POR inhibition with 2-chloroethyl ethyl sulfide: spontaneous formation of ROS was NADPH-dependent and concomitant with the inhibition of POR-mediated substrate reduction.

The high level of reactivity of aldehydes towards proteins probably limits both the amounts detectable in the biological matrix and their clinical assessment. However, Wang et al. [27] detected P-CHO in the urine and feces (0.2% and <0.1%, respectively) of mice treated with pazopanib (300 mg/kg). Co-treatment with aminobenzotriazole (100 mg/kg) decreased these levels, confirming the role of CYP450 in aldehyde production. They also observed that aldehyde abundance in the urine correlated significantly with serum transaminase activities ($r_{ALT} = 0.76, r_{AST} = 0.75, p < 0.05$). Similarly, we evaluated P-CHO accumulation in the plasma of patients treated with pazopanib, but we observed no correlation with reported hepatic side-effects. Indeed, we detected only a small amount of P-CHO in these samples (around 10 ng/mL, i.e., 22 nM for P-CHO), and the cohort was too small to identify a concentration-response relationship. The concentrations of aldehyde used in vitro were thus very high (>2000 times) compared to those observed in plasma, constituting a limitation in our observations. However, the high reactivity of such metabolites suggests that their circulating concentration in plasma may not reflect the intra-cellular amount and that the possibility of monitoring plasma aldehydes seems of limited interest. Given the known hepatotoxicity of these drugs and despite the difference of metabolites levels between in vitro and in vivo conditions, we cannot exclude that the dysfunctions observed in vitro may not occur at a clinical level.

Sunitinib biotransformation to oxidized products through CYP450 metabolism has been widely described in vitro, in vivo, and in humans [28,29]. However, other oxidation pathways may be considered, especially when involving highly reactive species. Indeed, the accumulation of superoxides following high concentrations of sunitinib may trigger spontaneous formation of $H_2O_2$ that is then further reduced in reactive hydroxyl radicals, thereby, *in fine*, possibly oxidizing sunitinib. This mechanism has been previously reported for adriamycin auto-oxidation in liver microsomes [30]. Nevertheless, our attempts to determine the origin of S-CHO and P-CHO led us to consider that a non-biological process could also contribute to aldehyde formation, as shown by its significant presence in sunitinib capsules, along with the impossibility of generating it with microsomes. Notably, Patel et al. [31] identified P-CHO as a photolytic degradation product of pazopanib. Although we detected extremely low levels of aldehyde (between 37 ppm and 330 ppm), they were above the 20 ppm limit imposed by the European Pharmacopoeia for an impurity of Imatinib mesylate, a precursor of a reactive quinone imine (4-methyl-N3-[4-(pyridin-3-yl)pyrimidin-2-yl] benzene-1,3-diamine) [32].

Finally, growing evidence suggests that reactive derivatives may activate an immune response and inflammation processes based on two major and complementary hypotheses. A reactive metabolite can act as a hapten to produce neoantigens (the hapten hypothesis), and the accumulation of these immunogenic molecules can cause cell damage followed by the release of danger-associated molecular patterns (DAMPs), activating antigen-presenting cells (APCs, the danger hypothesis) [33]. Kato et al. [34] tested the ability of gefitinib hepatic reactive metabolites to induce DAMP releases from monocytes. They showed that these metabolites could activate inflammasomes in APCs, a mechanism that could be similarly triggered by pazopanib or sunitinib.

To conclude, this study aimed to elucidate the contribution of pazopanib and sunitinib aldehyde derivatives to the mechanisms of TKI liver toxicity. Although electrophile aldehyde moiety is known to confer high levels of reactivity, the effects produced by P-CHO
and S-CHO are slightly different, but both alter the hepatocyte's function. Our findings demonstrated that the former may be responsible for a moderate but observable effect on the mitochondrial ability to produce ATP in HepG2 cells. A specific interaction of P-CHO was observed with NADPH-cytochrome P450 reductase (POR), whose consequence on CYP450 function should be further addressed. Moreover, hepatotoxicity is a complex issue depending on multiple mechanisms and interactions between biological pathways that need to be further understood.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/metabo12090852/s1. Figure S1: cytotoxicity of sunitinib, pazopanib and respective aldehydes after pre-treatment with BSO (250 µM). Figure S2: Proteomic analyses of microsomes incubated with pazopanib aldehyde (P-CHO). Figure S3: The MS/MS fragmentation spectrum of the EELAQFHRDGALTQLNVAFSR peptide (NADPH-cytochrome P450 reductase, Uniprot P16435) obtained after microsomes incubation with pazopanib aldehyde. Figure S4: metabolic pathways of production of P-CHO and S-CHO. Table S1: Variable modifications and their respective mass shifts, used for microsomes peptide identification.

**Author Contributions:** Conceptualization, C.A., C.C., E.C. and F.T.; formal analysis, M.M., C.A., F.P. and F.T.; investigation, M.M., C.V., N.J.C., F.P., N.S.-L. and T.L.; methodology, M.M., C.A. and F.T.; supervision, C.A., E.C. and F.T.; writing—original draft, M.M., C.A., E.C. and F.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** The clinical part of the study (plasma analysis in patients) was funded by a PHRCI grant from GIRCI-SOHO (Groupements Interrégionaux de Recherche Clinique et d'Innovation Sud Ouest Outre Mer Hospitaliers) (Study reference: EUDRACT 2015-001051-68).

**Institutional Review Board Statement:** The clinical study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee Comité de Protection des Personnes Sud-Ouest et Outre-Mer III (2015/59).

**Informed Consent Statement:** All subjects gave their informed consent for inclusion before they participated in the study.

**Data Availability Statement:** All data are in the Supplementary Materials and are available on request from the corresponding author.

**Acknowledgments:** The authors thank Cathy Quelen (Centre de Recherches en Cancérologie de Toulouse, France) for providing the HepG2 cell line and C. Guguen-Guillouzo (INSERM 991, Rennes, France) for providing the HepaRG cell line. The authors thank Gail Taillefer, University of Toulouse I—Capitole (Toulouse, France) for English-language editing of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Björnsson, E.S. Global Epidemiology of Drug-Induced Liver Injury (DILI). *Curr. Hepatol. Rep.* **2019**, *18*, 274–279. [CrossRef]

2. FDA Drug Approval Package: Votrient (Pazopanib). Application Number: 22-465. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000TOC.cfm (accessed on 10 July 2022).

3. FDA Drug Approval Package: Sutent (Sunitinib Malate) NDA #021938 & 021968. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938s000_021968s000_Stutent.cfm (accessed on 10 July 2022).

4. Eno, M.R.; El-Gendy, B.E.-D.M.; Cameron, M.D. P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2. *Chem. Res. Toxicol.* **2016**, *29*, 784–796. [CrossRef] [PubMed]

5. Xie, C.; Zhou, J.; Guo, Z.; Diao, X.; Gao, Z.; Zhong, D.; Jiang, H.; Zhang, L.; Chen, X. Metabolism and Bioactivation of Famitinib, a Novel Inhibitor of Receptor Tyrosine Kinase, in Cancer Patients. *Br. J. Pharmacol.* **2013**, *168*, 1687–1706. [CrossRef] [PubMed]

6. Paludetto, M.-N.; Stigliani, J.-L.; Robert, A.; Bernardes-Génisson, V.; Chatelut, E.; Puisset, F.; Arellano, C. Involvement of Pazopanib and Sunitinib Aldehyde Reactive Metabolites in Toxicity and Drug-Drug Interactions in Vitro and in Patient Samples. *Chem. Res. Toxicol.* **2020**, *33*, 181–190. [CrossRef]

7. Attwa, M.W.; Kadi, A.A.; Abdelhameed, A.S. Detection and Characterization of Olmutinib Reactive Metabolites by LC-MS/MS: Elucidation of Bioactivation Pathways. *J. Sep. Sci.* **2020**, *43*, 708–718. [CrossRef]
8. Stepan, A.F.; Walker, D.P.; Bauman, J.; Price, D.A.; Baillie, T.A.; Kalgutkar, A.S.; Aleo, M.D. Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. *Chem. Res. Toxicol.* **2011**, *24*, 1345–1410. [CrossRef]

9. Pessayre, D.; Mansouri, A.; Berson, A.; Fromenty, B. Mitochondrial Involvement in Drug-Induced Liver Injury. *Handb. Exp. Pharmacol.* **2010**, *196*, 311–365. [CrossRef]

10. Paech, F.; Mingard, C.; Grünig, D.; Abegg, V.F.; Bouitbir, J.; Krähenbühl, S. Mechanisms of Mitochondrial Toxicity of the Kinase Inhibitors Ponatinib, Regorafenib and Sorafenib in Human Hepatic HepG2 Cells. *Toxicology* **2018**, *395*, 34–44. [CrossRef]

11. Paech, F.; Abegg, V.F.; Duthaler, U.; Terracciano, L.; Bouitbir, J.; Krähenbühl, S. Sunitinib Induces Hepatocyte Mitochondrial Damage and Apoptosis in Mice. *Toxicology* **2018**, *409*, 13–23. [CrossRef]

12. Bouitbir, J.; Alshaikhali, A.; Panajatovic, M.V.; Abegg, V.F.; Paech, F.; Krähenbühl, S. Mitochondrial Oxidative Stress Plays a Critical Role in the Cardiotoxicity of Sunitinib. *Toxicology* **2019**, *426*, 152281. [CrossRef]

13. Mingard, C.; Paech, F.; Bouitbir, J.; Krähenbühl, S. Mechanisms of Toxicity Associated with Six Tyrosine Kinase Inhibitors in Human Hepatocyte Cell Lines. *J. Appl. Toxicol.* **2018**, *38*, 418–431. [CrossRef] [PubMed]

14. Paludetto, M.-N.; Bijani, C.; Puisset, F.; Bernardes-Génisson, V.; Arellano, C.; Robert, A. Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites. *J. Med. Chem.* **2018**, *61*, 7849–7860. [CrossRef] [PubMed]

15. Gripon, P.; Rumin, S.; Urban, S.; Seyec, J.L.; Glaise, D.; Cannie, I.; Guyomard, C.; Lucas, J.; Trepo, C.; Guguen-Guillouzo, C. Infection of a Human Hepatoma Cell Line by Hepatitis B Virus. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 15655–15660. [CrossRef] [PubMed]

16. Schmittgen, T.D.; Livak, K.J. Analyzing Real-Time PCR Data by the Comparative CT Method. *Nat. Protoc.* **2008**, *3*, 1101–1108. [CrossRef] [PubMed]

17. Xia, C.; Panda, S.P.; Marohnic, C.C.; Martasek, P.; Masters, B.S.; Kim, J.-J.P. Structural Basis for Human NADPH-Cytochrome P450 Oxidoreductase Deficiency. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 13486–13491. [CrossRef]

18. Andrade, R.J.; Chalasani, N.; Björnsson, E.S.; Suzuki, A.; Kullak-Ublick, G.A.; Watkins, P.B.; Devarbhavi, H.; Merz, M.; Lucena, M.I.; Kaplowitz, N.; et al. Drug-Induced Liver Injury. *Nat. Rev. Dis. Primers* **2019**, *5*, 1–22. [CrossRef]

19. Gerets, H.H.J.; Tilmant, K.; Gerin, B.; Chanteux, H.; Depelchin, B.O.; Dhalluin, S.; Atienzar, F.A. Characterization of Primary Human Hepatocytes, HepG2 Cells, and HepaRG Cells at the mRNA Level and CYP Activity in Response to Inducers and Their Predictivity for the Detection of Human Hepatotoxins. *Cell Biol. Toxicol.* **2012**, *28*, 69–87. [CrossRef]

20. Paech, F.; Bouitbir, J.; Krähenbühl, S. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. *Front. Pharmacol.* **2017**, *8*, 367. [CrossRef]

21. Mookerjee, S.A.; Divakaruni, A.S.; Jastroch, M.; Brand, M.D. Mitochondrial Uncoupling and Lifespan. *Mech. Ageing Dev.* **2010**, *131*, 463–472. [CrossRef]

22. Armstrong, J.S.; Steinauer, K.K.; Hornung, B.; Irish, J.M.; Lecane, P.; Birrell, G.W.; Peehl, D.M.; Knox, S.J. Role of Glutathione Depletion and Reactive Oxygen Species Generation in Apoptotic Signaling in a Human B Lymphoma Cell Line. *Cell Death Differ.* **2002**, *9*, 252–263. [CrossRef]

23. Wang, Y.; Branicky, R.; Noë, A.; Hekimi, S. Superoxide Dismutases: Dual Roles in Controlling ROS Damage and Regulating ROS Signaling. *J. Cell Biol.* **2018**, *217*, 1915–1928. [CrossRef] [PubMed]

24. Kandel, S.E.; Lampe, J.N. Role of Protein-Protein Interactions in Cytochrome P450-Mediated Drug Metabolism and Toxicity. *Chem. Res. Toxicol.* **2014**, *27*, 1474–1486. [CrossRef] [PubMed]

25. Mishin, V.; Gray, J.P.; Heck, D.E.; Laskin, D.L.; Laskin, J.D. Application of the Amplex Red/Horseradish Peroxidase Assay to Measure Hydrogen Peroxide Generation by Recombinant Microsomal Enzymes. *Free Radic. Biol. Med.* **2010**, *48*, 1485–1491. [CrossRef]

26. Gray, J.P.; Mishin, V.; Heck, D.E.; Laskin, D.L.; Laskin, J.D. Inhibition of NADPH Cytochrome P450 Reductase by the Model Sulfur Mustard Vesicant 2-Chloroethyl Ethyl Sulfide Is Associated with Increased Production of Reactive Oxygen Species. *Toxicol. Appl. Pharmacol.* **2010**, *247*, 76–82. [CrossRef] [PubMed]

27. Wang, Y.-K.; Yang, X.-N.; Liang, W.-Q.; Xiao, Y.; Zhao, Q.; Xiao, X.-R.; Gonzalez, F.J.; Li, F. A Metabolomic Perspective of Pazopanib-Induced Acute Hepatotoxicity in Mice. *Xenobiotica* **2019**, *49*, 655–670. [CrossRef]

28. Amaya, G.M.; Durandis, R.; Bourgeois, D.S.; Perkins, J.A.; Abouda, A.A.; Wines, K.J.; Mohamud, M.; Starks, S.A.; Daniels, R.N.; Jackson, K.D. Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib. *Chem. Res. Toxicol.* **2018**, *31*, 570–584. [CrossRef] [PubMed]

29. Speed, B.; Bu, H.-Z.; Pool, W.F.; Peng, G.W.; Wu, E.Y.; Patyna, S.; Bello, C.; Kang, P. Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans. *Drug Metab. Dispos.* **2012**, *40*, 539–555. [CrossRef] [PubMed]

30. Mimnaugh, E.G.; Trush, M.A.; Gram, T.E. Stimulation by Adriamycin of Rat Heart and Liver Microsomal NADPH-Dependent Lipid Peroxidation. *Biochem. Pharmacol.* **1981**, *30*, 2797–2804. [CrossRef]

31. Patel, P.N.; Kalariya, P.D.; Sharma, M.; Garg, P.; Talluri, M.V.N.K.; Gananadhamu, S.; Srinivas, R. Characterization of Forced Degradation Products of Pazopanib Hydrochloride by UHPLC-Q-TOF/MS and in Silico Toxicity Prediction. *J. Mass Spectrom.* **2015**, *50*, 918–928. [CrossRef]

32. *European Pharmacopoeia Imatinib Mesylate, Monography* 2736, 10th ed.; European Medicines Agency: Amsterdam, The Netherlands, 2017.
33. Cho, T.; Utrecht, J. How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction. *Chem. Res. Toxicol.* **2017**, *30*, 295–314. [CrossRef]

34. Kato, R.; Ijiri, Y.; Hayashi, T.; Utrecht, J. Reactive Metabolite of Gefitinib Activates Inflammasomes: Implications for Gefitinib-Induced Idiosyncratic Reaction. *J. Toxicol. Sci.* **2020**, *45*, 673–680. [CrossRef] [PubMed]